Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve (Q41127616)

27 September 2017

Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve (English)

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

18 October 2022

main subject

electroencephalography

1 reference

1 reference

schizophrenic psychology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1631250

18 October 2022

author name string

P. Czobor

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1631250

18 October 2022

J. Volavka

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1631250

18 October 2022

language of work or name

English

0 references

publication date

1 May 1992

1 reference

full work available at URL

27 September 2017

https://api.elsevier.com/content/article/PII:016517819290077G?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

https://api.elsevier.com/content/article/PII:016517819290077G?httpAccept=text/plain

18 October 2022

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

18 October 2022

1 reference

27 September 2017

42

1 reference

27 September 2017

2

1 reference

27 September 2017

129-144

1 reference

Vigilance and Evaluation of Psychotropic Drug Effects on EEG

27 September 2017

4

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Functional and anatomical brain imaging: impact on schizophrenia research.

18 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Pretreatment EEG predicts short-term response to haloperidol treatment

18 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Plasma homovanillic acid as a predictor of response to neuroleptics

18 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

The involvement of dopamine D1 and D2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine

18 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Use of the Research Diagnostic Criteria and the Schedule for Affective Disorders and Schizophrenia to study affective disorders

18 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

EEG and human psychopharmacology

18 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

C-EEG brain mapping in DSM-III schizophrenics after acute and chronic haloperidol treatment.

18 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Topographic factor analysis of the EEG with applications to development and to mental retardation

18 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Development of a classification rule for four clinical therapeutic psychotropic drug classes with EEG power-spectrum variables of human volunteers

18 October 2022

17

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

A Simple Sequentially Rejective Multiple Test Procedure

18 October 2022

18

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Qualitative and Quantitative EEG Findings in Schizophrenia

18 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Digital computer analyzed sleep and resting EEG during haloperidol treatment

18 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Computerized EEG as a Predictor of Drug Response in Treatment Resistant Schizophrenics

18 October 2022

25

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Developmental equations for the electroencephalogram.

18 October 2022

27

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

18 October 2022

Neurometrics

28

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Neurometrics: computer-assisted differential diagnosis of brain dysfunctions.

18 October 2022

30

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Computerized EEG in schizophrenia

18 October 2022

31

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

The effect of neuroleptics on cognitive and psychomotor function

18 October 2022

32

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Mesocorticolimbic dopaminergic network: functional and regulatory roles

18 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Neuroleptic plasma level may predict response in patients who meet a criterion for improvement

18 October 2022

34

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Concurrent lithium administration results in higher haloperidol levels in brain and plasma of guinea pigs.

18 October 2022

35

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

MANOVA method for analyzing repeated measures designs: an extensive primer.

18 October 2022

37

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain

18 October 2022

38

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol.

18 October 2022

43

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Quantitative EEG, SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy.

18 October 2022

44

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Research diagnostic criteria: rationale and reliability

18 October 2022

45

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

COMSTAT rule for vigilance classification based on spontaneous EEG activity

18 October 2022

46

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Prediction of neuroleptic on-drug response in schizophrenic in-patients by EEG

18 October 2022

47

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Dopamine and norepinephrine activity in schizophrenia. An integrative perspective

18 October 2022

49

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Haloperidol blood levels and clinical effects

18 October 2022

50

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

The effects of haloperidol on the EEG spectrum

18 October 2022

51

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Central D1- and D2-receptor occupancy during antipsychotic drug treatment

18 October 2022

52

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia

18 October 2022

53

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Dopamine receptor occupancy and plasma haloperidol levels

18 October 2022

54

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Drug trials and heterogeneity in schizophrenia: the mean is not the end

18 October 2022

55

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

18 October 2022

Identifiers

1 reference

27 September 2017

1 reference